Rasagilinum

Rasagilinum est medicamentum pharmaceuticum et inhibitor monoaminorum oxidasis B irreversibilis^[1]. Substantia in morbo Parkinson tractando et maturo^[2] et in cursibus progressivis.

Cave: notitiae huius paginae nec praescriptiones nec consilia medica sunt.

**Rasagilinum**
Cognitores
ChemSpider	2314553
PubChem	3052776
DrugBank	DB01367
Natura chemica


Formula chemica	C ₁₂H ₁₃N
Massa molaris	171.238 g/mol
Natura pharmacologica
Codex ATC	N04BD02 (WHO)
Semivita biologica	3 h
Metabolismus	iecore (hepaticus): CYP1A2
Excretio	renibus, faecibus
Ad usum therapeuticum
Applicatio	per os
MedlinePlus	a606017 (Anglice)

Natura Rasagilini

Natura chemica

Nomen suum est (R)-N-prop-2-inyl-2,3-dihydro-1H-inden-1-aminum. Massa molaris sua 171.238 g/mol.

Natura pharmacologica

Rasagilinum est MAO-B inhibitor irreversibilis et medicamentum therapia morbi Parkinson et maturi et progressivi. Codex ATC est N04BD02 (WHO). Inhibitio monoaminorum oxidasis B potentissima est, etenim quinquies, decies quam Selegilino.

Effectus Rasagilini

Interactiones

Consumptio simul Rasagilini et cuiusvis inhibitoris reabsorptionis serotonini (per exemplum: sertralinum) periculo syndromae serotonini causa saepe non commendatur^[3]^[4], quamquam investigatio Canadiensis syndroma serotoni raro esse dixit, donec doses inhibitoris reabsorptionis serotonini parve deligantur^[5].

Notae

↑ Oldfield V., Keating G. M., Perry C. M. (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725-47
↑ Hattori N., Takeda A., Takeda S., Nishimura A., Kitagawa T., Mochizuki H., Nagai M., Takahashi R. (2018). "Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan". Parkinsonism Relat Disord: doi: 10.1016/j.parkreldis.2018.08.024
↑ Hébant B., Guillaume M., Desbordes M., Gaillon G., Maltête D., Lefaucheur R. (2016). "Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient". Rev Neurol (Paris) 172 (12): 788-9
↑ Duval F., Flabeau O., Razafimahefa J., Spampinato U., Tison F. (2013). "Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome". Mov Disord 28 (10): 1464
↑ Aboukarr A., Giudice M. (2018). "Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors". Can J Hosp Pharm 71 (3): 196-207

Nexus interni

Morbus Parkinson

Nexus externi

Fabrizio Stocchi: Eritne somnus therapiae ad morbum tardandum verum? (oratio), (Italice)

[1] Oldfield V., Keating G. M., Perry C. M. (2007). "Rasagiline: a review of its use in the management of Parkinson's disease". Drugs 67 (12): 1725-47

[2] Hattori N., Takeda A., Takeda S., Nishimura A., Kitagawa T., Mochizuki H., Nagai M., Takahashi R. (2018). "Rasagiline monotherapy in early Parkinson's disease: A phase 3, randomized study in Japan". Parkinsonism Relat Disord: doi: 10.1016/j.parkreldis.2018.08.024

[3] Hébant B., Guillaume M., Desbordes M., Gaillon G., Maltête D., Lefaucheur R. (2016). "Combination of paroxetine and rasagiline induces serotonin syndrome in a parkinsonian patient". Rev Neurol (Paris) 172 (12): 788-9

[4] Duval F., Flabeau O., Razafimahefa J., Spampinato U., Tison F. (2013). "Encephalophaty associated with rasagiline and sertraline in Parkinson's disease: possible serotonin syndrome". Mov Disord 28 (10): 1464

[5] Aboukarr A., Giudice M. (2018). "Interaction between Monoamine Oxidase B Inhibitors and Selective Serotonin Reuptake Inhibitors". Can J Hosp Pharm 71 (3): 196-207

[1]

[2]

[3]

[4]

[5]